Tryp Therapeutics Reports the First Patient Dosing with TRP-8802 in P-IIa Clinical Trial for the Treatment of Fibromyalgia
Shots:
- The first patient has been dosed in a P-IIa clinical trial evaluating TRP-8802 in patients with fibromyalgia. The study is being conducted by Tyrp Therapeutics in collaboration with the University of Michigan
- Following the positive results demonstrated by the study, the company expects to continue the clinical development in fibromyalgia with TRP-8803 which addresses several setbacks associated with oral psilocin incl. reduced time to psychedelic state, regulating the intensity & duration of the psychedelic experience & reducing the overall duration of the intervention
- TRO-8802 is the precursor to TRP-8803, IV-infused psilocin with a unique formulation and delivery system to enhance psilocybin's positive effects
Ref: Tryp Therapeutics| Image: Tryp Therapeutics
Related News:- Silo Pharma with Sever Pharma Solutions Obtains Regulatory Approval to Conduct the Development of Ketamine Implant for Fibromyalgia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
